Research map: Changes in anthropometric parameters in children with cystic fibrosis treated with ivacaftor/tezacaftor/ elexacaftor and ivacaftor, with transition within a single INN, in the Republic of Bashkortostan

Back to the article

Papers in this map

  1. The future of cystic fibrosis care: a global perspective · Scott C Bell · 2019 · 988 citations · Cited by this paper
  2. Frequency of polymorphic variants of the IFNG (rs2069705) and IL28b (rs12979860) genes depending on the severity of clinical manifestations of Opisthorchis felineus invasion · 2026 · Related
  3. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis · Dominique Turck · 2016 · 526 citations · Cited by this paper
  4. Late therapeutic use of tauractant in infants with bronchopulmonary dysplasia: A retrospective comparative study · 2026 · Related
  5. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study · Julie K. Bower · 2023 · 138 citations · Cited by this paper
  6. Clinical significance of hyperammonemia in non-alcoholic fatty liver disease · 2026 · Related
  7. Targeted therapy for cystic fibrosis · Sergey Ivanovich Kutsev · 2021 · 26 citations · Cited by this paper
  8. Changes in results of a skin test with recombinant TB allergen during preventive chemotherapy in children exposed to TB cases · 2026 · Related
  9. Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry · Mordechai Pollak · 2025 · 16 citations · Cited by this paper
  10. Expiratory disproportion index as an additional parameter of clinical assessment in bilateral laryngeal paralysis · 2026 · Related
  11. Efficacy and safety of triple therapy (elexacaftor/tezacaftor/ ivacaftor) in children with cystic fibrosis: 12-month follow-up · E. Kondratyeva · 2024 · 10 citations · Cited by this paper
  12. Intestinal endometriosis: Current aspects of pathogenesis, clinical picture, and differential diagnosis (a review of foreign literature) · 2026 · Related
  13. Consensus-based guidance for the nutritional management of children with cystic fibrosis on ELEXACAFTOR/TEZACAFTOR/IVACAFTOR · Tamarah E. Katz · 2026 · 8 citations · Cited by this paper
  14. Neurological comorbidities in psoriasis and psoriatic arthritis: Neuropathic pain, cognitive impairment and cerebrovascular risk · 2026 · Related
  15. Evolving nutritional needs, obesity, and overweight status in cystic fibrosis · Sylvia E. Szentpetery · 2023 · 6 citations · Cited by this paper
  16. Combined therapy for infectious and inflammatory diseases of the upper respiratory tract (clinical observation) · 2026 · Related
  17. Study of the efficacy and safety of the generic drug ivacaftor + tezacaftor + elexacaftor/ivacaftor (trade name Trilexa®) · Е. И. Кондратьева · 2025 · 6 citations · Cited by this paper
  18. Efficacy of rebamipide in Helicobacter pylori eradication regimens: A review of recent experimental and clinical data · 2026 · Related
  19. Воспоминания о профессоре Капранове: простые истории · Ye. K. Ginter · 2025 · 5 citations · Cited by this paper
  20. Enterosorbents in the combination therapy of alcohol withdrawal syndrome · 2026 · Related
  21. Nutritional outcomes in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor: A 24-mo real-world study · Gianfranco Alicandro · 2025 · 5 citations · Cited by this paper
  22. Beyond BMI: Nutritional Recovery and Functional Implications of CFTR Modulators in Cystic Fibrosis · Giovanna Linguiti · 2026 · 2 citations · Cited by this paper
  23. Body composition in patients with cystic fibrosis, its impact on morbidity and survival rates, and its changes during targeted therapy · Н. А. Крылова · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)